Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995393 | 0.86 | ACHE (0.50) | MEN1TSHRKMT2ASIGMAR1ACHE | |
| SCHEMBL5974931 | 0.84 | CCR3 (0.57) | SIGMAR1DRD2DRD4DRD3ACHE | |
| SCHEMBL5975118 | 0.84 | CCR3 (0.57) | SIGMAR1DRD2DRD4DRD3ACHE | |
| SCHEMBL5974936 | 0.84 | CCR3 (0.57) | SIGMAR1DRD2DRD4DRD3ACHE | |
| SCHEMBL12706739 | 0.83 | SIGMAR1 (0.49) | SIGMAR1ACHEBCHE | |
| SCHEMBL31288163 | 0.82 | ACHE (0.53) | SIGMAR1DRD2DRD4DRD3ACHE | |
| Hydrochloric Acid SCHEMBL6660125 | 0.82 | CCR3 (0.55) | SIGMAR1DRD2ACHECCR3 | |
| SCHEMBL27596453 | 0.82 | ACHE (0.49) | SIGMAR1DRD2DRD4DRD3ACHE | |
| SCHEMBL3709844 | 0.79 | KMT2A (0.50) | MEN1TSHRKMT2ASIGMAR1DRD2 | |
| SCHEMBL11178158 | 0.79 | DRD2 (0.49) | SIGMAR1DRD2ACHECCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016192630-A1 | COMPOUND HAVING KINASE INHIBITING ACTIVITY, METHOD OF PREPARING SAME, AND USE OF SAME | 中国科学院上海药物研究所 | 2016-12-08 | — | — | WO | disclosed |
| US-7795262-B2 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1998620-A4 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1998620-A2 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | Neurogen Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007106349-A2 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | HRH3, HRH4, HRH1 | MEN1 2317/4885TSHR 314/4885KMT2A 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.